CalciMedica, Inc. received confirmation from Nasdaq that it complies with the alternative minimum stockholders’ equity requirement under Listing Rule 5550(b)(1), closing its non-compliance notice regarding market value of listed securities. The company previously implemented a one-for-five reverse stock split on August 28, 2026, to address this issue. However, CalciMedica remains in violation of the minimum bid price requirement and has until September 14, 2026, to regain compliance. The filing notes that there is no assurance the company will maintain listing standards. CalciMedica operates in the biotechnology industry, developing therapies for inflammatory diseases.
